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Lithium inhibits tumor 
lymphangiogenesis and metastasis 
through the inhibition of TGFBIp 
expression in cancer cells
Yong-Sun Maeng1, Rina Lee1, Boram Lee1, Seung-il Choi1 & Eung Kweon Kim1,2
Metastasis is the main cause of mortality in cancer patients. Although there are many anti-cancer 
drugs targeting tumor growth, anti-metastatic agents are rarely developed. Angiogenesis and 
lymphangiogenesis are crucial for cancer progression; in particular, lymphangiogenesis is pivotal 
for metastasis in cancer. Here we report that lithium inhibits colon cancer metastasis by blocking 
lymphangiogenesis. Lithium reduces the expression of transforming growth factor-β-induced 
protein (TGFBIp) in colon cancer cells by inhibiting Smad3 phosphorylation via GSK3β inactivation. 
Moreover, lithium inhibits lymphatic endothelial cell migration, which is increased upon TGFBIp 
expression in tumor cells. Lithium had no significant effect on SW620 tumor growth in vitro and 
in vivo; however, it inhibited lymphangiogenesis in tumors. In tumor xenografts model, lithium 
was found to prevent metastasis to the lungs, liver, and lymph nodes by inhibiting TGFBIp-induced 
tumor lymphangiogenesis. Collectively, our findings demonstrate a novel role of lithium in the 
inhibition of colon cancer metastasis by blocking TGFBIp expression, and thereby TGFBIp-induced 
lymphangiogenesis, in primary tumors.
Cancer metastasis follows an ordered and hierarchical pattern. Colorectal cancer cells initially spread to the 
lymph nodes and peritoneal area. When metastases to the liver occur, a substantial number of patients also 
develop lung, and less frequently bone or brain, metastases1. Patients with metastasis are treated with systemic 
chemotherapy, mostly in a palliative manner. Nevertheless, in selected patients with isolated liver metastasis, 
increased 5-year survival can be achieved by multimodal treatment that includes a combination of surgery with 
modern chemotherapy2. However, only about 25% of patients can benefit from this type of treatment, and the 
presence of metastases in other organs is, in most cases, a contraindication for resection3. Although metastatic 
tumor spread can occur via a variety of mechanisms, including direct local invasion of tissue or the seeding of 
body cavities, most metastases arise following invasion of, and dissemination via, the circulatory system.
Although anti-angiogenic agents have been used for treating cancer in the clinical setting, overall survival in 
advanced cancer patients has not been substantially improved4, possibly because cancer metastasis occurs pref-
erentially via lymphatic dissemination rather than hematogenous spread5–7. Indeed, in many human cancers, the 
detection of tumor metastases in the tumor-draining lymph node is the first step in tumor dissemination, and 
is one of the most important markers of both patient prognosis and therapeutic strategy decisions. Thus, there 
is an unmet need to develop therapeutic agents to block lymphangiogenesis as well as angiogenesis, in order to 
efficiently block tumor growth and metastasis.
Using bioinformatics-aided methodologies and in vitro and animal experiments, we have identified an extra-
cellular matrix protein that is involved in lymphangiogenesis8. We have reported that transforming growth 
factor-β -induced protein (TGFBIp) derived from cancer cells or lymphatic endothelial cells promotes lymphatic 
endothelial cell (LEC) migration, adhesion, and tube formation8. We have also documented that TGFBIp derived 
from colon cancer cells exhibits potent pro-lymphangiogenic activity in tumor xenografts8. Furthermore, we 
have shown that the inhibition of TGFBIp expression in cancer cells using the TGFBIp shRNA system decreases 
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tumor lymphangiogenesis and metastasis to distant organs8. However, TGFBIp had a minor effect on migration, 
tube formation, and sprouting of human umbilical vein endothelial cells, and the inhibition of TGFBIp expression 
showed only weak anti-angiogenic activity8. When tested separately, the anti-lymphangiogenic effect of inhibition 
of TGFBIp expression was significantly more potent than its anti-angiogenic activity in primary tumors8. Based 
on these findings, we suggested that TGFBIp exerts a stronger effect on lymphatic vessels than on blood vessels, 
and further that TGFBIp is a potential target to block tumor lymphangiogenesis and metastasis8.
Recently, several studies have revealed that GSK-3 inhibitors downregulate TGFBIp expression by blocking 
TGF-β signaling9–11. GSK-3 inactivation generally yields anti-apoptotic effects. A number of studies demonstrate 
that lithium directly inhibits GSK-312–17. Lithium also indirectly inhibits GSK-3 by triggering the phosphoryla-
tion of GSK-3 at ser21/ser918–20. Increasing evidence suggests that lithium elicits its neuroprotective effects by 
inhibiting GSK-321. Besides direct inhibition, lithium can block GSK-3 activity indirectly through the phospho-
rylation of GSK-3α at ser21 and of GSK-3β at ser9 by multiple mechanisms, including the activation of PKA22, 
phosphatidylinositol 3-kinase (PI3-K)-dependent AKT18, and protein kinase C (PKC)23, and autoregulation of 
GSK-320,24. One of our recent studies also demonstrated that lithium treatment reduces TGFBIp expression in a 
dose-dependent manner in corneal fibroblasts through the inactivation of GSK-325. Therefore, we investigated the 
effects of lithium on TGFBIp expression and lymphangiogenesis in colon cancer cells.
Here, we report the in vitro and in vivo activities of lithium in inhibiting TGFBIp expression, tumor lymphang-
iogenesis, and metastasis. Lithium reduces the expression of TGFBIp in SW620 colon cancer cells by inhibiting 
the transforming growth factor β 1-Smad3 signaling pathway via GSK3β inactivation. In addition, lithium inhibits 
lymphatic endothelial cell (LEC) migration induced by TGFBIp. Furthermore, we demonstrated that lithium has 
activity against lymphangiogenesis and angiogenesis, has no effect on the growth of a primary colon cancer tumor 
xenograft, and strongly inhibits its metastasis to the lungs, liver, and lymph nodes by blocking lymphangiogenesis 
in primary tumors. Taken together, these data suggest that lithium functions as an anti-tumor metastasis factor by 
inhibiting TGFBIp expression and TGFBIp-induced tumor lymphangiogenesis in primary tumors.
Results
Lithium inhibits TGFBIp expression in tumor cells. To assess the effect of lithium on TGFBIp expres-
sion in SW620 colon cancer cells, which highly expressed the TGFBIp protein8,26, colon cancer cells were cultured 
with lithium carbonate, and then TGFBIp expression was analyzed. The concentration of lithium carbonate used 
to treat cancer cells was determined empirically. Usually, high lithium doses, over 20 mM, are used for their effect 
on cancer27,28. However, high lithium doses did not affect TGFBIp expression in our experimental condition 
and low lithium doses (125–2000 μ M) only reduced of TGFBIp expression in cancer cells. Cancer cells cultured 
with lithium carbonate displayed significantly decreased TGFBIp protein and mRNA levels, and this effect was 
dose-dependent (Supplementary Fig. S1a, b online). Moreover, lithium carbonate inhibited TGFβ 1-induced 
TGFBIp expression in a dose-dependent manner (Supplementary Fig. S1c online).
The decrease in TGFBIp protein levels in response to lithium might occur via one of two mechanisms: lithium 
may enhance TGFBIp degradation or decrease TGFBIp biosynthesis. We previously demonstrated that autophagy 
is the main intracellular degradation pathway for TGFBIp and that lithium activates it through the PI3K signa-
ling pathway25,29. We also provided evidence indicating that the activation of autophagy enhances the cytosolic 
clearance of intracellular TGFBIp in corneal fibroblasts29. Therefore, we investigated the effect of lithium on auto-
phagy in cancer cells. However, lithium did not induce TGFBIp degradation via the autophagy-lysosome system 
(unpublished data).
The identification of Smad3/GSK-3 complexes30 suggests that GSK-3 can activate Smad3, a component of 
the TGFβ 1 signaling pathway; moreover, lithium is a well-established GSK-3 inhibitor. Therefore, we exam-
ined the effects of lithium on TGFBIp expression by investigating the TGFβ 1 signaling pathway. As shown in 
Supplementary Fig. S1d online, lithium carbonate decreased Smad3 phosphorylation in a dose-dependent man-
ner. In addition, lithium carbonate interacts with GSK-3α/β and negatively regulates its activity. Treatment of 
cancer cells with lithium carbonate significantly increased GSK-3β phosphorylation (Supplementary Fig. S1d 
online). Taken together, these results suggest that lithium reduces the expression of TGFBIp in colon cancer cells 
by inhibiting the TGFβ 1-Smad3 signaling pathway via GSK3β β inactivation.
Lithium had no effect on tumor growth. We evaluated the capacity of lithium to inhibit TGFBIp-induced 
tumor growth, angiogenesis, lymphangiogenesis, and metastasis in an animal model: a subcutaneous xenograft 
of the human colon cancer SW620 cell line that displays an aggressive metastatic pattern8,26. After tumor injec-
tion (5 × 106 cells/mouse), lithium carbonate was administered orally two times per week for up to 62 days 
(Supplementary Fig. S2 online). Equal numbers of SW620 cells were implanted subcutaneously into NOD-SCID 
mice, and the growth of the resultant primary tumors was monitored. Interestingly, there were no significant 
differences in the average size and weight of the tumors derived from control and lithium carbonate-treated 
mice (Fig. 1a–c). Mouse body weights were statistically identical among the two groups, demonstrating that 
lithium carbonate does not have severe toxic effects (unpublished data). Additional western blot assays showed 
that TGFBIp protein levels were significantly reduced in tumors derived from lithium carbonate-treated mice, 
compared with those from controls (Fig. 1d). Additionally, in vitro growth rates were not modified by lithium 
treatment (Supplementary Fig. S3 online). These data demonstrate that lithium had no significant effect on tumor 
growth in vitro and in vivo.
Lithium reduces tumor lymphangiogenesis. To determine whether lithium could inhibit tumor angi-
ogenesis and lymphangiogenesis, tumors were sectioned and stained for lymphatic- or blood vessel-specific 
markers, LYVE-1 and CD31, respectively. Tumors derived from lithium-treated mice showed a very low 
density of lymphatic vessels stained with LYVE-1/CD31 in the peri-tumoral (margin of tumor) (Fig. 2a) 
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and intratumoral (central region of tumor) areas (Fig. 2b and Supplementary Fig. S4 online). Quantification 
of LYVE-1/CD31-positive lymphatic structures confirmed that vessel density was significantly reduced in 
lithium-treated tumors as compared with controls (Fig. 2c). However, only CD31-positive blood vessel density 
was slightly decreased in lithium-treated tumors (Fig. 2c).
To further validate the effect of lithium on tumor lymphangiogenesis by TGFBIp expressed in tumor cells, a 
Transwell migration assay was performed. As shown in Supplementary Fig. S5 online, tumor cell increased the 
migration of LECs, which were used as a positive control. However, lithium-treated tumor cells showed decreased 
migration of LECs, and this migration was re-increased by TGFBIp treatment. These results indicate that lithium 
reduces tumor (lymph)angiogenesis by inhibiting TGFBIp expression in tumor cells in vitro and in vivo.
Lithium inhibits tumor metastasis. Finally, to evaluate the effects of lithium on tumor metastasis via 
the lymphatic system, tumor-bearing mice were sacrificed and examined for metastases in the lung and liver. 
Microscopic analysis of the lungs and livers revealed a significant decrease in the number of metastatic nodules 
per lung or liver from lithium-treated mice versus control mice (Fig. 3a,c), which was confirmed by quantification 
of the number of metastatic nodules per lung or liver (Fig. 3b,d). Moreover, immunohistochemical analysis and 
tumor cell-specific CCR7 staining revealed significantly reduced lung (Figs 3a, 4a and Supplementary Fig. S6a 
online) and liver metastases (Figs 3c, 4b and Supplementary Fig. S6b online) in lithium-treated mice, compared 
with control mice. Strikingly, lithium treatment inhibits the incidence of lateral axillary lymph node metastasis, 
and histological analysis showed reduced metastatic colon cancer cells in the lymph node in lithium-treated mice 
versus control mice (Fig. 5a–d and Supplementary Fig. S7 online). Overall, our data suggest that lithium treat-
ment is useful to suppress the metastatic potential of colon cancer cells via the lymphatic system without affecting 
the growth rate of tumors.
Discussion
Generally, after the removal of malignant tumors by surgery, radiation therapy and/or adjuvant treatment with 
chemotherapy may be curative. However, the removal of certain cancers, for example breast carcinomas, colon 
carcinomas, and osteogenic sarcomas, may be followed by rapid metastasis to the lung, liver, and kidney through 
neovascularization and/or to regional lymph nodes through the lymphatic system6,7,31–37. Therefore, it is necessary 
to develop new anticancer agents with anti-tumor and anti-metastatic activities. Several reports have shown that 
Figure 1. Lithium carbonate had no effect on tumor growth. SW620 cells were injected subcutaneously 
into the midline of the backs of NOS-SCID mice (n = 5 per group). After tumor cell inoculation, mice were 
randomized to receive either 125 mg/kg lithium carbonate (Li2CO3) in 100 μ L deionized water (d.H2O), or 
100 μ L d.H2O alone, two times per week by oral gavage, from the time of tumor inoculation. Tumors were 
removed after 62 days, excised, and serially sectioned. (a) Representative tumors. (b,c) Analysis of tumor 
growth rates and weights. (d) TGFBIp protein levels in tumors derived from lithium- or control-injected mice 
were measured by western blotting.
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lithium is effective in inhibiting glioma38, colorectal cancer39, medulloblastoma40, hepatocellular carcinoma41, and 
other cancer cells42. In fact, it has been suggested that the lower cancer prevalence observed in mental patients 
is likely due to a protective benefit derived from lithium treatment43. At the molecular level, lithium has been 
shown to inhibit the growth and/or tumorigenicity of cancer cells by modulating the biological activities of 
many cancer-related genes, such as STAT344, b-catenin/WNT39,40, TNF42, FASL45 and P5346. Lithium, an effective 
GSK3β inhibitor, has been used in treating depression and bipolar disorder for many years47. Recently, it has been 
shown that inhibition of GSK3β promotes apoptosis in glioma cells and PDA cells48,49, and sensitizes PANC-1 
cells to gemcitabine50. In addition, lithium induces apoptosis in a variety of cancer cells45,51. At present, the mech-
anism of lithium-mediated anti-cancer activity is not clear, and the anti-metastatic actions of lithium have yet to 
be demonstrated in vitro and in vivo.
We previously reported that TGFBIp is a lymphangiogenic factor that induces metastasis via three probable 
mechanisms: (1) by increasing lymphatic density and consequently augmenting surface contact with cancer cells; 
(2) by increasing CCL21 expression in LECs and promoting the migration of cancer cells; and (3) by increasing 
lymphatic permeability and facilitating the intravasation and/or extravasation of tumor cells8 (Supplementary 
Fig. S8 online). Based on these findings, we suggested that TGFBIp might be a potential therapeutic target 
for treating metastatic colon cancer. Inhibition of TGFBIp expression using a TGFBIp-specific shRNA lenti-
virus in tumor cells or LECs dramatically reduced adhesion, migration, lymphatic sprouting of LECs, and 
tumor lymphangiogenesis and metastasis in vitro and in vivo. These finding suggest that inhibition of TGFBIp 
expression helps suppress the metastatic potential of colon cancer cells via owing to the consequent reduced 
lymphangiogenesis8.
In this study, we investigated the inhibitory effect of lithium on TGFBIp expression, tumor lymphangiogen-
esis, and metastasis in vitro and in vivo. Interestingly, our results show a significant downregulation of TGFBIp 
expression in colon cancer cells following lithium treatment, and further demonstrate that lithium induces this 
effect by inhibiting Smad3 phosphorylation though GSK3β inactivation. Several studies indicate that GSK-3 
inhibitors downregulate TGFBIp expression by blocking TGFβ signaling9–11. To test this hypothesis, we analyzed 
the expression of TGFBIp in cancer cells treated with lithium. Western blot analysis showed that lithium treat-
ment reduced the levels of TGFBIp in a dose-dependent manner. Quantitative RT-PCR indicated that lithium 
Figure 2. Lithium-carbonate reduces tumor lymphangiogenesis in colon cancer. (a) Margins of tumor 
sections were stained for infiltrating LECs using anti-LYVE1 and anti-CD31 antibodies. Nuclei were stained 
with DAPI (blue fluorescence). Arrows indicate lymphatic vessels. Yellow dotted lines point to the margins 
of the tumor. Images were viewed using an Olympus IX81-ZDC microscope with a LUCPL FLN 10×/1.0 NA 
lens. (b) Central regions of tumor sections were stained for infiltrating LECs using anti-LYVE1 and anti-CD31 
antibodies. Nuclei were stained with DAPI (blue fluorescence). Arrows indicate lymphatic vessels. Images 
were viewed by using an Olympus IX81-ZDC microscope with a LUCPL FLN 10×/1.0 or 2.0 NA lens.  
(c) Quantitative assessment of LYVE1- and CD31-positive lymphatic vessels per field for each tumor section. 
Data are presented as the mean ± S.E. **P < 0.01 vs. control group.
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treatment decreased TGFBIp mRNA expression in a dose-dependent manner, suggesting that the regulation of 
TGFBIp occurs at the transcriptional level. In addition, we analyzed whether lithium could inhibit TGFβ 1-SMAD 
signaling by blocking GSK-3 activity. We found that lithium negatively regulated GSK-3 activity and decreased 
Smad3 phosphorylation, thereby reducing TGFBIp expression in a dose-dependent manner. However, lithium 
did not induce TGFBIp degradation via the autophagy-lysosomal system, the main intracellular degradation 
pathway for TGFBp29. Collectively, these results suggest that lithium reduces the expression of TGFBIp in cancer 
cells by inhibiting the TGFβ 1-Smad3 signaling pathway through the inactivation of GSK3β .
In addition, TGFBIp expression in tumors of mice with subcutaneously implanted SW620 colon cancer cells 
was significantly reduced in lithium-treated mice compared with control mice. Interestingly, there was no sig-
nificant difference in the average size and weight of tumors in control and lithium-treated mice, and the in vitro 
growth rates were not influenced by lithium treatment. These results suggest that low lithium doses in our exper-
imental conditions only reduce TGFBIp expression but may not be sufficient to inhibit proliferation or induce 
apoptosis in cancer cells. Usually, high lithium doses affect cancer proliferation or apoptosis27,28. In addition, the 
effect of lithium on tumor growth may not only dependent on the inhibition of TGFBIp expression, but also on 
the regulation of oncogenes such as STAT3,β -catenin/WNT, TNF, FASL, and P53. This possibility needs to be 
investigated in further studies.
Inhibition of TGFBIp expression in cancer cells by lithium decreased tumor metastasis to the lungs, liver, and 
lymph nodes. Based on immunohistochemical observations, lithium strongly reduced the number of lymphatic 
vessels (LYVE-1/CD31-positive cells) in the peri- and intra-tumoral areas. However, the density of blood vessels 
that were only CD31-positive was slightly decreased in lithium-treated tumors, suggesting that lithium has a 
stronger effect on lymphatic vessels than on blood vessels. Lymphatic vessels with wider lumens were observed 
in control tumors expressing high levels of TGFBIp, and were correlated with increased tumor metastasis to the 
lungs, liver, and lymph nodes. To further evaluate the effect of lithium on tumor lymphangiogenesis by TGFBIp 
expressed in tumor cells, an in vitro transwell migration assay was performed. Tumor cells expressing high lev-
els of TGFBIp showed increased LEC migration. However, lithium-treated tumor cells showed decreased LEC 
migration, and this migration was increased by TGFBIp treatment. These results demonstrate that lithium inhib-
its tumor (lymph)angiogenesis by inhibiting TGFBIp expression in tumor cells in vitro and in vivo.
Furthermore, analysis of tumor cell metastasis in mouse organs revealed a significant decrease in the number 
of metastatic nodules per lung or liver, as well as reduced lateral axillary lymph node metastasis, in lithium-treated 
mice as compared with control mice. Our data suggest that the inhibition of TGFBIp by lithium administration is 
useful to suppress the metastatic potential of colon cancer cells via the lymphatic system.
Figure 3. Lithium carbonate suppresses tumor metastases to lung and liver. (a,c) Images of lung and liver 
metastases of mice injected with SW620 cells, and hematoxylin and eosin staining of frozen sections of lung 
and liver tissues isolated from mice subcutaneously injected with SW620 cells. (b,d) The number of metastatic 
nodules per lung or liver was quantified by microscopic inspection. **P < 0.01 vs. control group. Black dotted 
lines indicate metastatic tumors in the mouse lung or liver. Data are presented as the mean ± s.e. **P < 0.01 vs. 
control group.
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The anti-metastatic activity of lithium provides clinical insights and a rationale for using lithium as an agent to 
prevent metastasis in cancer patients in neoadjuvant settings. In the neoadjuvant setting, where the tumor is not 
excised during chemotherapy, the stressed tumor may secrete factors to promote angiogenesis and lymphangio-
genesis at distant sites, in order to allow it to move to a more favorable site where the local tumor microenviron-
ment may protect it. If such patients with cancer cells expressing high levels of TGFBIp are treated with lithium, 
possibly in combination with chemotherapeutics, metastatic lymphatic vessel formation would be inhibited. As a 
result, secondary recurrence of the tumor, including metastases, may be more effectively prevented.
In summary, our findings clearly demonstrate a novel role of lithium to inhibit colon cancer metasta-
sis by blocking TGFBIp expression, and thereby TGFBIp-induced lymphangiogenesis, in primary tumors 
(Supplementary Fig. S8 online). As lymphangiogenesis is central to metastatic cell dissemination and metastatic 
disease is the primary cause of death in cancer, lithium could be a potential treatment for metastatic disease.
Methods
Cell culture. SW620 cells were purchased from the Korean Cell Line bank (Seoul, Korea) and cultured in 
Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (FBS) and antibiotics.
Cell migration assay. Cell migration was assayed using the Transwell system (Corning Costar, Acton, MA) 
with 6.5 mm-diameter polycarbonate filters (8-μ m pore size). Briefly, (group 1, 2) the lower surface of the fil-
ter was coated with 10 μ g/ml gelatin. LECs (105) were seeded onto chemotaxis filters, and recombinant human 
TGFBIp (rhTGFBIp; 10 μ g/ml; Sino Biological Inc., Beijing, China) was then added to the lower chamber. (group 
3, 4) the lower surface of the filter was coated with 10 μ g/ml gelatin. SW620 tumor cells were seeded in the lower 
chamber until confluence and were either treated with TGFBIp (10 μ g/ml) or not. LECs (105) were seeded onto 
chemotaxis filters. (group 5) the lower surface of the filter was coated with 10 μ g/ml gelatin. SW620 tumor cells 
were seeded in the lower chamber until confluence and treated with lithium carbonate (2000 μ M) for 60 min. 
After a change in media, LECs (105) were seeded onto chemotaxis filters. (group 6) the lower surface of the filter 
was coated with 10 μ g/ml gelatin. SW620 tumor cells were seeded in the lower chamber to confluence and treated 
with or without lithium carbonate (2000 μ M) for 60 min. After a change of media, TGFBIp (10 μ g/ml) was then 
added to the lower chamber. LECs (105) were seeded onto chemotaxis filters. After the 12-hour migration period, 
non-migrating cells were completely removed from the top surface of the membrane. Migrating cells adhering 
to the undersurface of the filters were detected by hematoxylin and eosin (H&E) staining and quantified using 
Kodak 1D software (Eastman Kodak, Rochester, NY). Results are representative of three different experiments, 
each performed in duplicate.
Figure 4. Lithium carbonate suppresses CCR7+ tumor metastases to lung and liver. (a,b) CCR7 staining of 
frozen sections of lung and liver tissues isolated from mice subcutaneously injected with SW620 cells. Arrows 
indicate CCR7-positive metastatic tumors in the mouse lung or liver.
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Real-time quantitative reverse transcription polymerase chain reaction (Real-time qRT-PCR). Total 
RNA was isolated from SW620 cells by extraction in TRIZOL reagent (Invitrogen, Carlsbad, CA). Using the 
Power SYBR Green RNA-to-CTTM 1-Step kit (Applied Biosystems, Foster City, CA) and StepOnePlusTM (Applied 
Biosystems), mRNA expression levels of the human GAPDH and TGFBIp genes were measured according to the 
manufacturer’s instructions. The PCR conditions for all genes were as follows: 48 °C for 30 min, 95 °C for 10 min, 
then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The results are based on cycle threshold (Ct) values. We calcu-
lated differences between the Ct values for experimental and reference genes (GAPDH) and graphed the results 
as the ratio of each RNA to the calibrator sample. The primers used for gene amplification were as follows: TGFBI 
5′ -CACAGTCTTTGCTCCCACAA-3′ (sense) and 5′ -CTCCGCTAACCAGGATTTCA-3′ . (antisense); GAPDH 
5′ -ATGGGGAAGGTGAAGGTCG-3′ (sense) and 5′ -GGGGTCATTGATGGCAACAATA-3′ (antisense). Three 
independent experiments were performed, and statistical analysis was carried out using Newman-Keuls multiple 
comparison tests.
Immunofluorescence staining and immunohistochemistry. Eight micrometer-thick frozen tumor 
sections were washed in phosphate-buffered saline (PBS) and blocked in 5% normal donkey serum in an antibody 
dilution buffer consisting of PBS containing 0.1% Triton X-100. Sections were then incubated overnight in pri-
mary antibody (rat anti-mouse CD31 monoclonal antibody; Clone: MEC 13.3, 1:200 dilution, BD PharMingen, 
San Diego, CA) or rabbit anti-mouse LYVE1 polyclonal antibody (1:200 dilution, Angiobio Co., Del Mar, CA) at 
4 °C, and labeled with a fluorescein-conjugated secondary antibody (Molecular Probes, Leiden, The Netherlands). 
Nuclei were counterstained with DAPI and are seen in blue. Samples were observed with a fluorescence micro-
scope (Olympus, Tokyo, Japan). The number of lymphatic vessels within the tumor was counted in six fields per 
section: the center regions of the tumor (to measure intra-tumor vessel density) and within an area 1 mm from 
the tumor border (to measure peri-tumor vessel density). Seven slide sections per mouse were analyzed. To deter-
mine the metastasis of SW620 tumor cells to the mouse lateral axillary lymph nodes, lungs, and liver, sections 
Figure 5. Lithium carbonate suppresses tumor metastasis to the lymph nodes. (a) Lateral axillary lymph 
node morphology of tumor-bearing groups (n = 5 per group). (b,d) Hematoxylin and eosin, and CCR7 staining 
of frozen sections of lateral axillary lymph node tissues isolated from mice subcutaneously injected with SW620 
cells. (c) The incidence of metastasis per lateral axillary lymph node was quantified by microscopic analysis. 
Data are presented as the mean ± s.e. **P < 0.01 vs. control group.
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of mouse lymph nodes, lungs, and liver (seven slide sections per mouse) were stained with H&E and rabbit 
anti-CCR7 monoclonal antibody (Clone: Y59, 1:200 dilution, Abcam Inc. Cambridge, MA).
Mouse tumor models and in vivo procedures. SW620 cancer cells were harvested from subconfluent 
cell culture plates, washed with PBS, and resuspended at a concentration of 2.5 × 107 cells per ml DMEM contain-
ing 10% FBS. Of the suspended cells, an aliquot of 0.2 ml (5 × 106 cells/ mouse) was injected subcutaneously into 
the right posterior flank of 5-week-old NOD-SCID mice (Orient Company, Korea) with five mice in each group. 
Three days after tumor cell inoculation, mice were randomized to receive either 125 mg/kg Lithium carbonate 
(Li2CO3) in 100 μ L deionized water (d.H2O) or 100 μ L d.H2O alone two times per week by oral gavage, from the 
time of tumor inoculation until the time of humane killing. The serum levels of lithium in treated animals were 
in the range of 0.7–1.2 mmol/L. We monitored the mice for signs of lithium toxicity, such as weight loss or behav-
ioral changes, and observed none. Tumors were measured with calipers to estimate volumes on days 1 to 62 after 
injection. Eight weeks after injection, mice were sacrificed and the tumors were resected and weighed. All organs 
were removed for examination, and metastases to lateral axillary lymph nodes around the tumor region, lungs, 
and liver were detected by H&E staining and quantified by counting the metastatic lesions in each section. All 
studies were repeated twice to ensure reproducibility (with a minimum of five mice per group).
Animal studies. The mice were housed and maintained under sterile conditions in facilities accredited by the 
Korean Association of Assessment and Accreditation of Laboratory Animal Care. This study was carried out in 
strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of Yonsei 
University. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Yonsei 
University. All efforts were made to minimize animal suffering.
Western blotting. Cell lysates were fractionated by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred to polyvinyl difluoride membranes. The blocked membranes were incubated 
with the appropriate antibody, and the immunoreactive bands were visualized with a chemiluminescent reagent 
as recommended by Amersham Biosciences, Inc., Piscataway, NJ.
Statistical analysis. All experiments were repeated at least three times. Data are presented as the 
means ± standard error (S.E.), and statistical comparisons between groups were performed by one-way ANOVA 
followed by Tukey’s test.
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